A meta-analysis of 41 studies of neonatal or predischarge mortality among live-born infants weighing less than or equal to 1,500 g or those born at less than or equal to 32 weeks' gestation showed that these very low birth weight or very preterm infants were at significantly higher risk of death if they were born in a facility other than a level 3 hospital.
A meta-analysis of 41 studies of neonatal or predischarge mortality among live-born infants weighing less than or equal to 1,500 g or those born at less than or equal to 32 weeks' gestation showed that these very low birth weight (VLBW) or very preterm (VPT) infants were at significantly higher risk of death if they were born in a facility other than a level 3 hospital.
According to a study conducted by the Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion of the Centers for Disease Control and Prevention, VLBW infants born in hospitals less than level 3 had a 62% increase in the odds of neonatal or predischarge death than those born in level 3 hospitals (38% vs 23%). When the analysis was restricted to only higher-quality evidence (from 9 of the 41 studies), these odds were nearly as high: 60%.
In addition, VLBW infants (=1,000 g) born in less than level 3 hospitals had an estimated 80% increase in the odds of mortality compared with babies born at level 3 hospitals (59% vs 32%).
Lassell SM, Barfield WD, Rochat RW, Blackmon L. Perinatal regionalization for very low-birth-weight and very preterm infants: a meta-analysis. JAMA. 2010;304(9):992-1000.
Mosie Baby Kit receives class 2 FDA clearance for intravaginal insemination
December 6th 2023Discover how Mosie Baby's at-home insemination kit, the first FDA-cleared of its kind, empowers individuals facing infertility challenges with an effective, easy-to-use solution for intravaginal insemination.
Read More
Daré Bioscience initiates phase 3 clinical trial for ovaprene contraceptive
December 5th 2023Daré Bioscience has commenced a pivotal phase 3 clinical trial for ovaprene, an intravaginal contraceptive that releases a locally acting agent to prevent sperm entry into the cervical canal, marking a significant step towards a non-hormonal contraceptive option for women.
Read More
Exploring menstrual health: Insights from the Avon longitudinal study
December 5th 2023Unveiling a comprehensive analysis of menstrual cycle characteristics in mothers and daughters, this article delves into the diverse features, potential risk factors, and the importance of understanding these nuances for effective menstrual health management.
Read More
How plasma biomarkers illuminate brain health in women with HIV
December 4th 2023Discoveries from a comprehensive study reveal specific plasma biomarkers that may serve as indicators of neurological well-being in individuals living with HIV, shedding light on potential links to Alzheimer's disease and emphasizing the importance of early detection for improved outcomes.
Read More